We are live on ! Find out more
MAM

MPM Asset Management Portfolio holdings

AUM $44.5M
1-Year Est. Return 47.28%
This Fund
S&P 500
This Quarter Est. Return
+20.77%
1 Year Est. Return
-47.28%
3 Year Est. Return
+5.89%
5 Year Est. Return
-18.52%
10 Year Est. Return
+3.53%
AUM
$204M
AUM Growth
+$16.8M
Cap. Flow
-$412K
Cap. Flow %
-0.2%
Top 10 Hldgs %
100%
Holding
7
New
Increased
Reduced
1
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ADAP
Adaptimmune Therapeutics
ADAP
+$412K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TRDA icon
1
Entrada Therapeutics
TRDA
$273M
$66.8M 32.82%
4,425,784
DYN icon
2
Dyne Therapeutics
DYN
$4.68B
$65.9M 32.36%
4,951,303
ITOS
3
DELISTED
iTeos Therapeutics
ITOS
$30M 14.74%
2,738,785
HOWL icon
4
Werewolf Therapeutics
HOWL
$45.8M
$16.5M 8.13%
4,284,172
RPTX
5
DELISTED
Repare Therapeutics
RPTX
$16.4M 8.04%
2,242,636
ADAP
6
DELISTED
Adaptimmune Therapeutics
ADAP
$4.41M 2.16%
5,555,461
-731,640
-12% -$412K
HARP
7
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$3.56M 1.75%
313,136

Similar funds

MPM Asset Management's Q4 2023 Portfolio in Review

As of Q4 2023, MPM Asset Management held 7 positions worth $204M, up 9% from $187M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q4 2023: portfolio turnover was 0%. MPM Asset Management opened no new positions and made no exits, leaving the 7-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM Asset Management's biggest Q4 2023 reduction was Adaptimmune Therapeutics, cutting an estimated $412K.
  • MPM Asset Management's ten largest holdings make up 100% of its $204M portfolio in Q4 2023.
  • MPM Asset Management opened 0 new positions and closed 0 in Q4 2023.
  • MPM Asset Management's portfolio value rose 9% quarter-over-quarter to $204M.

Based on MPM Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.